Given that astrocyte activation is observed with autism and FXS16, 60, it is tempting to speculate that astrocyte derived proteases contribute to altered neuroplasticity in these conditions and more specifically, that the MMP-1/PAR1 signaling axis could represent a therapeutic target. The gene discussed is F2R; the disease is autism.